iBio is an innovator biologics company developing therapeutics and vaccines for the betterment of human and animal health with pipeline candidates targeting systemic sceleroderma (IBIO-100), COVID-19 (IBIO-200 and IBIO-201), and classical swine fever (IBIO-400). iBio’s subsidiary, iBio CDMO is a global leader in plant-based manufacturing. It’s FastPharming® and FastGlycaneering™ platforms provide contract development and manufacturing services via its 130,000 square foot facility in Bryan, Texas. The speed and scalability of FastPharming make it an ideal choice for other innovator companies who want to rapidly produce biologics.


November 24, 2020

iBio Announces Issuance of U.S. Patent Covering Endostatin Peptides for Treating Fibrosis

- Methods for Production in iBio’s FastPharming® System Foundational to Antifibrotic Development ...

November 3, 2020

iBio Announces Appointment of Randy J. Maddux as Chief Operating Officer

- Brings >20 Years of Global Biotech Operations and Business Development Experience - BRYAN, Texas, ...

October 2, 2020

iBio Enters into Agreement with Safi Biosolutions to Develop Growth Factors and Cytokines Using the FastPharming® System

- Project Focused on Proteins used in the Production of Blood Cells - NEW YORK, Oct. 02, 2020 ...